TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia October 31, 2003